» Articles » PMID: 24529189

ARA 290, a Peptide Derived from the Tertiary Structure of Erythropoietin, Produces Long-term Relief of Neuropathic Pain Coupled with Suppression of the Spinal Microglia Response

Overview
Journal Mol Pain
Date 2014 Feb 18
PMID 24529189
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Neuropathic pain is a difficult to treat disorder arising from central or peripheral nervous system lesions. The etiology of neuropathic pain consists of several overlapping pathways converging into an exaggerated pain state with symptoms such as allodynia and hyperalgesia. One of these pathways involves activation of spinal cord microglia and astrocytes, which drive and maintain the inflammatory response following the lesion. These cells are a potential target for drugs for neuropathic pain relief. In this current study, we investigated the dose-effect relationship of the tissue protective peptide ARA 290, derived from the tertiary structure of erythropoietin, on allodynia and concurrent spinal cord microglia and astrocytes.

Results: Following a spared nerve injury in rats, vehicle or ARA290 (administered in either one of 4 doses: 3, 10, 30 and 60 μg/kg) was administered on days 1, 3, 6, 8 and 10. ARA290 exerted a dose-response effect by significantly reducing mechanical allodynia up to 20 weeks when compared to vehicle. The reduction of cold allodynia was significant up to 20 weeks for the doses 3, 10, 30 and 60 μg/kg when compared to vehicle. The effect 10 and 30 μg/kg ARA290 and vehicle on the microglia response (iba-1-immunoreactivity, iba-1-IR) and astrocyte reaction (GFAP-immunoreactivity, GFAP-IR) was investigated in animals surviving 2 (group 1) or 20 (group 2) weeks following lesion or sham surgery. In group 1, significant microglia reactivity was observed in the L5 segment of the spinal cord of animals treated with vehicle when compared to sham operated, while animals treated with 10 or 30 μg/kg did not show a increase. In group 2, a more widespread and increased microglia reactivity was observed for animals treated with 0 and 10 μg/kg when compared to sham operated animals, indicated by involvement of more spinal cord segments and higher iba-1-IR. Animals treated with 30 μg/kg did not show increased microglia reactivity. No difference in astrocyte reaction was observed.

Conclusions: The erythropoietin-analogue ARA290 dose-dependently reduced allodynia coupled to suppression of the spinal microglia response, suggestive of a mechanistic link between ARA290-induced suppression of central inflammation and relief of neuropathic pain symptoms.

Citing Articles

Mechanisms of ARA290 in counteracting cadmium-triggered neurotoxicity in PC12 cells.

Motafeghi F, Fakhri B M, Ghassemi Barghi N Toxicol Res (Camb). 2025; 14(1):tfaf023.

PMID: 39968520 PMC: 11831023. DOI: 10.1093/toxres/tfaf023.


Microglial EPOR Contribute to Sevoflurane-induced Developmental Fine Motor Deficits Through Synaptic Pruning in Mice.

He D, Shi X, Liang L, Zhao Y, Ma S, Cao S Neurosci Bull. 2024; 40(12):1858-1874.

PMID: 38907076 PMC: 11625042. DOI: 10.1007/s12264-024-01248-5.


A small erythropoietin derived non-hematopoietic peptide reduces cardiac inflammation, attenuates age associated declines in heart function and prolongs healthspan.

Winicki N, Nanavati A, Morrell C, Moen J, Axsom J, Krawczyk M Front Cardiovasc Med. 2023; 9:1096887.

PMID: 36741836 PMC: 9889362. DOI: 10.3389/fcvm.2022.1096887.


Nonerythropoietic Erythropoietin Mimetic Peptide ARA290 Ameliorates Chronic Stress-Induced Depression-Like Behavior and Inflammation in Mice.

Xu G, Zou T, Deng L, Yang G, Guo T, Wang Y Front Pharmacol. 2022; 13:896601.

PMID: 36046815 PMC: 9421426. DOI: 10.3389/fphar.2022.896601.


Linking erythropoietin to Treg-dependent allograft survival through myeloid cells.

Horwitz J, Bin S, Fairchild R, Keslar K, Yi Z, Zhang W JCI Insight. 2022; 7(10).

PMID: 35389892 PMC: 9220923. DOI: 10.1172/jci.insight.158856.


References
1.
Brines M, Patel N, Villa P, Brines C, Mennini T, De Paola M . Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci U S A. 2008; 105(31):10925-30. PMC: 2504825. DOI: 10.1073/pnas.0805594105. View

2.
Mennini T, De Paola M, Bigini P, Mastrotto C, Fumagalli E, Barbera S . Nonhematopoietic erythropoietin derivatives prevent motoneuron degeneration in vitro and in vivo. Mol Med. 2006; 12(7-8):153-60. PMC: 1626597. DOI: 10.2119/2006-00045.Mennini. View

3.
Ren K, Dubner R . Interactions between the immune and nervous systems in pain. Nat Med. 2010; 16(11):1267-76. PMC: 3077564. DOI: 10.1038/nm.2234. View

4.
Iwasaki R, Matsuura Y, Ohtori S, Suzuki T, Kuniyoshi K, Takahashi K . Activation of astrocytes and microglia in the C3-T4 dorsal horn by lower trunk avulsion in a rat model of neuropathic pain. J Hand Surg Am. 2013; 38(5):841-6. DOI: 10.1016/j.jhsa.2013.01.034. View

5.
Milligan E, Twining C, Chacur M, Biedenkapp J, OConnor K, Poole S . Spinal glia and proinflammatory cytokines mediate mirror-image neuropathic pain in rats. J Neurosci. 2003; 23(3):1026-40. PMC: 6741915. View